Adult; Aged; Bone Marrow Purging; Drug Contamination; Hematopoietic Stem Cell Transplantation; Humans; Lymphoma, Non-Hodgkin/mortality/therapy; Middle Aged; Survival Rate; Treatment Outcome
Abstract :
[en] Intensification using peripheral blood stem cells collected after chemotherapy followed by growth factors is being increasingly investigated as an alternative to conventional chemotherapy for mantle cell non-Hodgkin lymphoma. We investigated 14 grades III-IV, t(11;14)-positive cases for contamination of PBSC collected after a polychemotherapy regimen followed by G-CSF. Patients were first treated with a polychemotherapy regimen. There were four CR, seven PR, two refractory and one early death. Seven patients have been transplanted, in whom PBSC were mobilized, using either cyclophosphamide/VP16 or Dexa-BEAM followed by G-CSF. For all patients, whether actually autografted or not, PB cells were tested at the time of regeneration on G-CSF after the first polychemotherapy or after the mobilizing regimen. PCR evaluation of contamination was performed first by a semi-quantitative approach, using serial dilutions of initial DNA, then confirmed using a limiting-dilution analysis. Two patients were not informative (one early death and one without an available molecular marker). PB cells collected at regeneration contained at least one log more lymphoma cells than steady-state blood or marrow, apart from in two cases. Moreover, where a mobilizing treatment diminished tumor burden in the patient, at the same time it increased PB contamination in most cases. We conclude that advanced mantle cell NHL appears to be largely resistant to significant in vivo purging by conventional chemotherapy. Where treatment brings benefits by reducing tumor load, it may at the same time negate it by mobilizing malignant cells into the collections used to intensify. Although the clonogenic potential of this massive infiltration is unknown (only gene marking studies could provide a definitive answer regarding the source of relapses), strategies aimed at reducing the level of contamination in the graft should be considered when designing future protocols.
Disciplines :
Hematology
Author, co-author :
Jacquy, Caroline
Lambert, Frédéric ; Centre Hospitalier Universitaire de Liège - CHU > Génétique
Soree, A.
Van Daele, S.
Heusterspreute, M.
Bosly, A.
Ferrant, A.
Parma, J.
Bron, D.
Martiat, P.
Language :
English
Title :
Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging?
Harris NL, Jaffe ES, Stein H et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361-1392.
Weisenburger DD, Armitage JO. Mantle cell lymphoma, an entity comes of age. Blood 1996; 87: 4483-4490.
Zucca E, Soldati G, Schlegelberger B et al. Detection of chromosome 11 alterations in blood and bone marrow by interphase cytogenetics in mantle cell lymphoma. Br J Haematol 1995; 89: 665-671.
Bigoni R, Negrini M, Veronese ML et al. Characterization of t(11;14) translocation in mantle cell lymphoma by fluorescent in situ hybridization. Oncogene 1996; 13: 797-803.
Uchimaru K, Taniguchi T, Yoshikawa M et al. Detection of Cyclin D1 overexpression by a simple competitive reverse transcription-polymerase chain reaction assay in t(11;14)-bearing B-cell malignancies and/or mantle cell lymphoma. Blood 1997; 89: 965-974.
Bosch F, Lopez-Guillermo A, Campo E et al. Mantle cell lymphoma: presenting features, response to therapy, and prognostic factors. Cancer 1998; 82: 567-575.
Vandenberghe E, De Wolf-Peeters C, Vaughan Hudson G et al. The clinical outcome of 65 cases of mantle cell lymphoma initially treated with non-intensive therapy by the British National Lymphoma Investigation Group. Br J Haematol 1997; 99: 842-847.
Segal GH, Masih AS, Fox AC et al. CDS-expressing B cell non Hodgkin's lymphomas with bcl-1 gene rearrangement have a relatively homogeneous immunophenotype and are associated with an overall poor prognosis. Blood 1995; 85: 1570-1577.
Philip T, Armitage JO, Spitzer G et al. High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma. New Engl J Med 1987; 316: 1493-1498.
Takvorian T, Canellos G, Ritz J et al. Prolonged disease-free survival after autologous bone marrow transplantation in patients with non-Hodgkin's lymphoma with poor prognosis. New Engl J Med 1987; 316: 1499-1506.
Adkins D, Brown R, Goodnough LT et al. Treatment of resistant mantle cell lymphoma with allogeneic bone marrow transplantation. Bone Marrow Transplant 1998; 21: 97-99.
Kroger N, Hoffknecht M, Dreger P et al. Long-term disease-free survival of patients with advanced mantle-cell lymphoma following high-dose chemotherapy. Bone Marrow Transplant 1998; 21: 55-57.
Blay JY, Sebban C, Surbiguet C et al. High-dose chemotherapy with hematopoietic stem cell transplantation in patients with mantle cell or diffuse centrocytic non-Hodgkin's lymphomas: a single center experience on 18 patients. Bone Marrow Transplant 1998; 21: 51-54.
Freedman AS, Neuberg D, Gribben JG et al. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission. J Clin Oncol 1998; 16: 13-18.
Andersen NS, Donovan JW, Borus JS et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997; 90: 4212-4221.
Ketterer N, Salles G, Espinouse D et al. Intensive therapy with peripheral stem cell transplantation in 16 patients with mantle cell lymphoma. Ann Oncol 1997; 8: 701-704.
Dreger P, von Neuhoff N, Kuse R et al. Sequential high-dose therapy and autologous stem cell transplantation for treatment of mantle cell lymphoma. Ann Oncol 1997; 8: 401-403.
Corradini P, Astolfi M, Cherasco C et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin lymphomas treated with high-dose chemotherapy and peripheral blood progenitor autografting. Blood 1997; 89: 724-731.
Stewart DA, Vose JM, Weisenburger DD et al. The role of high dose therapy and autologous hematopoietic stem cell transplantation for mantle cell lymphoma. Ann Oncol 1995; 6: 263-269.
Aubin J, Davi F, Nguyen-Salomon F et al. Description of a novel FR1 IGH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia 1995; 9: 470-479.
Nizet Y, Martiat P, Vaerman JL et al. Follow-up of residual disease (MRD) in B lineage acute leukaemias using a simplified PCR strategy: evolution of MRD rather than its detection is correlated with clinical outcome. Br J Haematol 1991; 79: 205-210.
Nizet Y, Van Daele S, Lewalle P et al. Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogeneic IGH probes and the polymerase chain reaction. Blood 1993; 82: 1618-1625.
Jacquy C, Delepaut B, Van Daele S et al. A prospective study of minimal residual disease in childhood B-lineage acute lymphoblastic leukaemia: MRD level at the end of induction is a strong predictive factor of relapse. Br J Haematol 1997; 98: 140-146.
Heusterspreute M, Derclaye I, Gala JL et al. Beta thalassemia in indigenous Belgian families: identification of a novel mutation. Hum Genet 1996; 98: 77-79.
Landman-Parker J, Aubin J, Delabesse E et al. Simplified strategies for minimal residual disease detection in B-cell precursor acute lymphoblastic leukaemia. Br J Haematol 1996; 95: 281-290.
Shiach CR, Evans PA, Short MA et al. Detection and accurate sizing of PCR products by automated scanning; improved detection of immunoglobulin gene rearrangements in ALL. Br J Haematol 1993; 85: 431-433.
Sykes PJ, Neoh SH, Brisco MJ et al. Quantitation of targets for PCR by use of limiting dilution. Biotechniques 1992; 13: 444-448.
Ouspenskaia M, Johnston D, Roberts W et al. Accurate quantitation of residual B-precursor acute lymphoblastic leukemia by limiting dilution and a PCR-based detection system: a description of the method and the principles involved. Leukemia 1995; 9: 321-328.
Kurokawa T, Kinoshita T, Murate T et al. Complementarity determining region-III is a useful molecular marker for the evaluation of minimal residual disease in mantle cell lymphoma. Br J Haematol 1997; 98: 408-412.